disulfiram glutathione in liver diseases: a double-edged sword | Naunyn-Schmiedeberg's Archives of Pharmacology Biotransformation and reaction of DS
Description
The possibility of protein conformational alterations induced by the reducing agents, resulting in decreased adduct formation, cannot be excluded
Many inhibitors targeting specific HDAC subtypes and HDAC pan-inhibitors have been shown to have renoprotective effects and may be potential strategies for future kidney disease treatment (Bush and McKinsey, 2010
They, therefore, suggested administering a second dose of PRP where necessary at about three months in the case of partial recovery as a boost dose [23]
The peptide comes as lyophilized powder requiring reconstitution with bacteriostatic water before use
